Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals discovers and develops medicines in cellular metabolism. Lead product is PYRUKYND (mitapivat) for hemolytic anemias. Developing AG-946 for lower-risk myelodysplastic syndrome and hemolytic anemias, and AG-181 for phenylketonuria. Also developing siRNA for polycythemia vera, a rare blood disorder. Company was incorporated in 2007. Headquartered in Cambridge, Massachusetts.
Overview
Strengths
- Pricing power: gross margin has held between 88% and 89% over the last 4 years (latest 88.3%).
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 3.0% in each of the last 7 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 7 of the last 7 years.
- Unstable profitability: operating margin ranged from -2,732% to -362% over the last 5 years, with operating losses in 5 of them.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data